Effectiveness of polyene phosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research.
Expert Rev Clin Pharmacol
; 15(11): 1363-1375, 2022 Nov.
Article
en En
| MEDLINE
| ID: mdl-36062967
ABSTRACT
OBJECTIVES:
Polyene phosphatidylcholine (PPC) is a widely used hepatoprotective drug. We aim to explore the effectiveness of PPC in patients with liver diseases based on real-world research, and compare with other hepatoprotective drugs.METHODS:
This was a 'three-phase' retrospective study, including a descriptive study, a self-control case study, and a specific-disease cohort study. A total of 14,800 hospitalized patients were enrolled in phase I from 1 January 2015 to 1 January 2020, of which 793 patients using PPC alone were included for phase II and III. The major measurement of effectiveness analysis was the ALT level and its changes. Wilcoxon signed-rank test, Chi-square test, and Mann-Whitney U test were used.RESULTS:
In patients without liver tumor, ALT level decreased after using PPC (p < 0.01), and the decrease in ALT level using PPC was greater than using glutathione or magnesium isoglycyrrhizinate alone (p = 0.044; p = 0.038). In patients without liver tumor but having abnormal liver function, the decrease in ALT level using PPC + glutathione was greater than using glutathione alone (p = 0.047).CONCLUSION:
PPC had a beneficial effect on liver function in patients without liver tumor, and PPC could enhance the liver protective function of glutathione and magnesium isoglycyrrhizinate.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Hepáticas
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Expert Rev Clin Pharmacol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China